Assuntos
Benzodiazepinas/uso terapêutico , Butiratos/uso terapêutico , Colestase Intra-Hepática/tratamento farmacológico , Benzodiazepinas/efeitos adversos , Benzodiazepinas/economia , Benzodiazepinas/farmacologia , Butiratos/efeitos adversos , Butiratos/economia , Butiratos/farmacologia , Ensaios Clínicos como Assunto , Interações Medicamentosas , HumanosRESUMO
OBJECTIVE: We examined the role of butyric acid, a short-chain fatty acid formed by fermentation in the large intestine, in the regulation of insulin sensitivity in mice fed a high-fat diet. RESEARCH DESIGN AND METHODS: In dietary-obese C57BL/6J mice, sodium butyrate was administrated through diet supplementation at 5% wt/wt in the high-fat diet. Insulin sensitivity was examined with insulin tolerance testing and homeostasis model assessment for insulin resistance. Energy metabolism was monitored in a metabolic chamber. Mitochondrial function was investigated in brown adipocytes and skeletal muscle in the mice. RESULTS: On the high-fat diet, supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6 mice. Fasting blood glucose, fasting insulin, and insulin tolerance were all preserved in the treated mice. Body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondrial function and biogenesis was observed in skeletal muscle and brown fat. The type I fiber was enriched in skeletal muscle. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression was elevated at mRNA and protein levels. AMP kinase and p38 activities were elevated. In the obese mice, supplementation of butyrate led to an increase in insulin sensitivity and a reduction in adiposity. CONCLUSIONS: Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance in mouse. The mechanism of butyrate action is related to promotion of energy expenditure and induction of mitochondria function.
Assuntos
Butiratos/farmacologia , Metabolismo Energético/efeitos dos fármacos , Resistência à Insulina/fisiologia , Insulina/fisiologia , Síndrome Metabólica/prevenção & controle , Tecido Adiposo Marrom/efeitos dos fármacos , Tecido Adiposo Marrom/metabolismo , Animais , Temperatura Corporal/efeitos dos fármacos , Butiratos/uso terapêutico , Gorduras na Dieta/metabolismo , Histona Desacetilases/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Mitocôndrias Musculares/efeitos dos fármacos , Mitocôndrias Musculares/metabolismo , Fibras Musculares Esqueléticas/efeitos dos fármacos , Fibras Musculares Esqueléticas/metabolismo , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Obesidade/metabolismo , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transativadores/efeitos dos fármacos , Transativadores/genética , Fatores de TranscriçãoRESUMO
Forty patients with severe asthenia were subjected to clinical, neurological, psychometric, and neurophysiologic examination before and after Enerion therapy. Psychoneurophysiological assessment with cognitive evoked potentials P300 and psychometric tests revealed serious impairment of cognitive functions in patients before therapy (compared to healthy individuals). Enerion therapy decreased the degree of psychoautonomic syndrome and asthenia and improved cognitive functions.
Assuntos
Astenia/psicologia , Astenia/reabilitação , Cognição/fisiologia , Adolescente , Adulto , Idoso , Astenia/tratamento farmacológico , Sistema Nervoso Autônomo/fisiopatologia , Butiratos/uso terapêutico , Estudos de Casos e Controles , Cognição/efeitos dos fármacos , Potenciais Evocados P300/fisiologia , Feminino , Humanos , Masculino , Memória/fisiologia , Pessoa de Meia-Idade , Testes Neuropsicológicos , Psicometria/métodos , Psicotrópicos/uso terapêutico , Inquéritos e Questionários , Síndrome , Resultado do Tratamento , Percepção Visual/efeitos dos fármacos , Percepção Visual/fisiologiaRESUMO
BACKGROUND: The purpose of this study was to determine cost of care for leg ulcers in sickle cell patients and suggest an improved modality in ulcer care. STUDY DESIGN: We performed a retrospective study of a group of sickle cell disease patients with leg ulcers. RESULTS: Eighteen patients with a leg ulcer (duration: mean, 53.7 months), sickle cell disease, and a mean of 20.7 years of age had various modalities of treatment with the only consistency in healing being a commercial moist-wound dressing. CONCLUSIONS: There is no consistency in the treatment of the sickle cell patient with a leg ulcer. Treatment with a moist dressing had the best results.
Assuntos
Anemia Falciforme/complicações , Úlcera da Perna/terapia , Curativos Oclusivos/economia , Adolescente , Adulto , Arginina/análogos & derivados , Arginina/uso terapêutico , Curativos Hidrocoloides , Butiratos/uso terapêutico , Coloides , Terapia Combinada , Análise Custo-Benefício , Eritropoetina/uso terapêutico , Feminino , Custos Hospitalares , Humanos , Úlcera da Perna/economia , Úlcera da Perna/fisiopatologia , Tempo de Internação/economia , Masculino , Proteínas Recombinantes/uso terapêutico , Recidiva , Estudos Retrospectivos , Cicatrização/fisiologiaRESUMO
An assessment was made of the local use of 0.1% hydrocortisone 17-butyrate in the treatment of 15 patients with a variety of skin conditions involving face and neck. Treatment was used on a short-term basis ranging from 3 to 22 days. There was marked clinical improvement of the lesions in 12 patients. The results of this short study are in accord with earlier published work and suggest that this new nonfluorinated steroid has promising potential.